美康生物
(300439)
| 流通市值：30.17亿 | | | 总市值：39.66亿 |
| 流通股本：2.92亿 | | | 总股本：3.84亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 687,701,523.61 | 559,862,038.24 | 728,636,326.23 | 597,362,712.31 |
| 交易性金融资产 | 195,226,892.6 | 220,669,188.22 | 161,081,517.67 | 255,380,288.89 |
| 应收票据及应收账款 | 540,628,318.25 | 568,035,083.2 | 553,259,349.12 | 584,730,344.17 |
| 其中：应收票据 | 1,156,643.05 | 1,393,694.65 | 237,051.6 | - |
| 应收账款 | 539,471,675.2 | 566,641,388.55 | 553,022,297.52 | 584,730,344.17 |
| 应收款项融资 | 507,411.89 | - | 3,902,406.4 | 3,757,839.26 |
| 预付款项 | 65,785,806.35 | 51,432,761.91 | 30,136,636.11 | 43,869,139.08 |
| 其他应收款合计 | 12,834,843.62 | 15,214,149.78 | 15,555,082.5 | 19,241,477.55 |
| 存货 | 258,881,202.23 | 271,270,681.93 | 286,010,777.6 | 262,040,140.17 |
| 一年内到期的非流动资产 | 53,573,017.12 | - | - | - |
| 其他流动资产 | 42,605,968.49 | 34,940,894.09 | 45,612,248.83 | 31,693,233 |
| 流动资产合计 | 1,857,744,984.16 | 1,721,424,797.37 | 1,824,194,344.46 | 1,798,075,174.43 |
| 非流动资产: | | | | |
| 长期股权投资 | 168,226,302.04 | 182,410,127.93 | 185,728,046.12 | 171,533,446.33 |
| 其他权益工具投资 | 5,000,000 | 5,000,000 | 5,000,000 | 5,000,000 |
| 固定资产 | 1,335,586,654.3 | 1,336,718,194.06 | 1,350,989,826.87 | 995,393,574.65 |
| 在建工程 | 15,291,059.05 | 10,581,716.7 | 11,989,459.09 | 301,565,682.69 |
| 使用权资产 | 47,568,930.63 | 52,853,344.04 | 53,281,352.15 | 38,606,430.47 |
| 无形资产 | 129,642,829.44 | 131,900,586.38 | 135,425,698.35 | 122,258,116.33 |
| 长期待摊费用 | 32,803,338.15 | 35,827,419.56 | 39,818,352.49 | 28,198,745.04 |
| 递延所得税资产 | 52,537,026.49 | 49,302,563.68 | 40,748,986.09 | 43,674,924.35 |
| 其他非流动资产 | 10,872,696.54 | 61,922,946.62 | 57,938,441.18 | 58,892,770 |
| 非流动资产合计 | 1,797,528,836.64 | 1,866,516,898.97 | 1,880,920,162.34 | 1,765,123,689.86 |
| 资产总计 | 3,655,273,820.8 | 3,587,941,696.34 | 3,705,114,506.8 | 3,563,198,864.29 |
| 流动负债: | | | | |
| 短期借款 | - | - | 30,022,083.33 | 30,022,083.33 |
| 应付票据及应付账款 | 344,170,319.94 | 314,098,645.19 | 369,411,086.77 | 313,209,221.66 |
| 其中：应付票据 | 35,534,711.51 | 20,253,656.03 | 7,001,544.18 | - |
| 应付账款 | 308,635,608.43 | 293,844,989.16 | 362,409,542.59 | 313,209,221.66 |
| 合同负债 | 55,532,818.87 | 62,576,772.49 | 63,781,691.55 | 50,313,950.19 |
| 应付职工薪酬 | 53,999,583.4 | 40,539,575.01 | 91,409,533.11 | 77,094,159.09 |
| 应交税费 | 21,627,179.91 | 16,778,465.8 | 21,926,145.4 | 28,749,888.43 |
| 其他应付款合计 | 108,395,345.86 | 65,385,802.54 | 66,992,373.87 | 68,024,229.65 |
| 应付股利 | 21,767,330.56 | - | - | - |
| 一年内到期的非流动负债 | 13,883,823.22 | 15,011,925.5 | 15,787,509.62 | 11,522,232.34 |
| 其他流动负债 | 7,168,492.1 | 8,073,740.41 | 8,107,407.97 | 6,477,442.9 |
| 流动负债合计 | 604,777,563.3 | 522,464,926.94 | 667,437,831.62 | 585,413,207.59 |
| 非流动负债: | | | | |
| 租赁负债 | 33,748,678.24 | 35,958,747.46 | 37,110,955.12 | 24,592,483.45 |
| 预计负债 | 3,886,209.14 | 3,589,882.72 | 3,801,785.53 | - |
| 递延收益 | 26,936,666.7 | 20,683,333.36 | 17,020,000.02 | 16,248,666.68 |
| 递延所得税负债 | 40,680,832.99 | 41,994,187.97 | 46,275,590.69 | 56,540,560.5 |
| 非流动负债合计 | 105,252,387.07 | 102,226,151.51 | 104,208,331.36 | 97,381,710.63 |
| 负债合计 | 710,029,950.37 | 624,691,078.45 | 771,646,162.98 | 682,794,918.22 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 384,318,815 | 383,949,815 | 383,949,815 | 383,949,815 |
| 资本公积 | 1,123,258,259.9 | 1,121,481,826.83 | 1,120,321,345.63 | 1,118,487,183.12 |
| 减:库存股 | 2,911,750 | 5,823,500 | 5,823,500 | 5,907,940.75 |
| 其他综合收益 | -15,875,070.55 | -17,828,472.42 | -16,938,127.25 | -32,379,021.54 |
| 盈余公积 | 134,591,669.5 | 134,591,669.5 | 134,591,669.5 | 121,181,021.44 |
| 未分配利润 | 1,328,728,315.97 | 1,354,125,393.04 | 1,323,727,670.3 | 1,303,504,699.43 |
| 归属于母公司股东权益合计 | 2,952,110,239.82 | 2,970,496,731.95 | 2,939,828,873.18 | 2,888,835,756.7 |
| 少数股东权益 | -6,866,369.39 | -7,246,114.06 | -6,360,529.36 | -8,431,810.63 |
| 股东权益合计 | 2,945,243,870.43 | 2,963,250,617.89 | 2,933,468,343.82 | 2,880,403,946.07 |
| 负债和股东权益合计 | 3,655,273,820.8 | 3,587,941,696.34 | 3,705,114,506.8 | 3,563,198,864.29 |
| 公告日期 | 2025-08-29 | 2025-04-26 | 2025-04-19 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |